DE69315842T2 - Peptidverbindungen - Google Patents
PeptidverbindungenInfo
- Publication number
- DE69315842T2 DE69315842T2 DE69315842T DE69315842T DE69315842T2 DE 69315842 T2 DE69315842 T2 DE 69315842T2 DE 69315842 T DE69315842 T DE 69315842T DE 69315842 T DE69315842 T DE 69315842T DE 69315842 T2 DE69315842 T2 DE 69315842T2
- Authority
- DE
- Germany
- Prior art keywords
- peptide compounds
- peptide
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929215780A GB9215780D0 (en) | 1992-07-24 | 1992-07-24 | Peptide compounds |
PCT/GB1993/001558 WO1994002506A1 (en) | 1992-07-24 | 1993-07-23 | Peptide compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69315842D1 DE69315842D1 (de) | 1998-01-29 |
DE69315842T2 true DE69315842T2 (de) | 1998-04-09 |
Family
ID=10719254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69315842T Expired - Fee Related DE69315842T2 (de) | 1992-07-24 | 1993-07-23 | Peptidverbindungen |
Country Status (7)
Country | Link |
---|---|
US (1) | US5882645A (de) |
EP (1) | EP0652896B1 (de) |
AU (1) | AU4715493A (de) |
DE (1) | DE69315842T2 (de) |
ES (1) | ES2111167T3 (de) |
GB (1) | GB9215780D0 (de) |
WO (1) | WO1994002506A1 (de) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994011015A1 (en) * | 1992-11-12 | 1994-05-26 | Molecular Dynamics, Inc. | Lipophilic peptide-based carriers for targeted drug delivery using rational drug-binding design |
AUPM885194A0 (en) * | 1994-10-14 | 1994-11-10 | Council Of The Queensland Institute Of Medical Research, The | Synthetic peptides and vaccines comprising same |
JP2001502658A (ja) * | 1996-04-03 | 2001-02-27 | ペプレサーチ・エー/エス | 非樹状中心骨格ペプチド担体 |
DE69704269T2 (de) | 1997-06-11 | 2001-11-22 | Univ London Pharmacy | Dendritische, lysinhaltige Polypeptide zur gezielten Arzneimittelabreichung |
US7018637B2 (en) * | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
US7081495B1 (en) | 1998-09-23 | 2006-07-25 | School Of Pharmacy, University Of London | Cationic compounds and their use as macro molecular carriers |
DE69912827T2 (de) * | 1998-09-29 | 2004-10-21 | Loke Diagnostics Aps Aarhus | "ligand presenting assembly" (lpa), verfahren zu dessen herstellung und verwendungen |
US7018654B2 (en) * | 1999-03-05 | 2006-03-28 | New River Pharmaceuticals Inc. | Pharmaceutical composition containing an active agent in an amino acid copolymer structure |
US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US6716452B1 (en) * | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
GB9912911D0 (en) * | 1999-06-04 | 1999-08-04 | Zeneca Ltd | Chemical process |
GB9915074D0 (en) * | 1999-06-28 | 1999-08-25 | Cortecs Plc | Ligand-binding composition |
US6774102B1 (en) * | 1999-09-29 | 2004-08-10 | Gambro Dialysatoren Gmbh & Co. Kg | Extracorporeal endotoxin removal method |
US7163918B2 (en) | 2000-08-22 | 2007-01-16 | New River Pharmaceuticals Inc. | Iodothyronine compositions |
US20020099013A1 (en) * | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
CA2421374C (en) * | 2000-09-06 | 2017-03-07 | Aventis Pharma S.A. | Methods and compositions for diseases associated with amyloidosis |
DE10048417A1 (de) * | 2000-09-29 | 2002-04-11 | Roche Diagnostics Gmbh | Verbindungen mit verzweigtem Linker |
US8394813B2 (en) | 2000-11-14 | 2013-03-12 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
ITMI20011708A1 (it) * | 2001-08-03 | 2003-02-03 | Bracco Imaging Spa | Coniugati di peptidi, loro derivati con complessi metallici e utilizzo per i'indagine diagnostica tramite imaging per risonanza magnetica(m |
US7314956B2 (en) | 2001-08-08 | 2008-01-01 | Vaxim, Inc. | Multifunctional carrier for the delivery of a pharmacological agent or genetic material into a cell |
US7338939B2 (en) * | 2003-09-30 | 2008-03-04 | New River Pharmaceuticals Inc. | Abuse-resistant hydrocodone compounds |
US20070066537A1 (en) * | 2002-02-22 | 2007-03-22 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
US7375082B2 (en) * | 2002-02-22 | 2008-05-20 | Shire Llc | Abuse-resistant hydrocodone compounds |
US20060014697A1 (en) * | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
US7169752B2 (en) * | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
AU2002365162A1 (en) | 2001-11-14 | 2003-07-09 | Northwestern University | Self-assembly and mineralization of peptide-amphiphile nanofibers |
US20030229013A1 (en) * | 2001-12-07 | 2003-12-11 | Shih-Kwang Wu | Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same |
WO2003070749A2 (en) | 2002-02-15 | 2003-08-28 | Northwestern University | Self-assembly of peptide-amphiphile nanofibers under physiological conditions |
US7659253B2 (en) * | 2002-02-22 | 2010-02-09 | Shire Llc | Abuse-resistant amphetamine prodrugs |
AU2003219863C1 (en) * | 2002-02-22 | 2009-03-05 | Shire Llc | Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
US7105486B2 (en) * | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
US7700561B2 (en) * | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
EP1481078A4 (de) * | 2002-02-22 | 2006-08-16 | New River Pharmaceuticals Inc | Verwendung einer peptid-arzneistoff-konjugation zur reduzierung der variabilität von arzneistoff-serumspiegeln zwischen patienten |
US7554021B2 (en) | 2002-11-12 | 2009-06-30 | Northwestern University | Composition and method for self-assembly and mineralization of peptide amphiphiles |
WO2004046167A2 (en) | 2002-11-14 | 2004-06-03 | Northwestern University | Synthesis and self-assembly of abc triblock bola peptide |
US20040101901A1 (en) * | 2002-11-27 | 2004-05-27 | Piotr Tabaczewski | Novel lipophilic complexes for insertion of receptors into lipid membranes |
US20050112087A1 (en) * | 2003-04-29 | 2005-05-26 | Musso Gary F. | Pharmaceutical formulations for sustained drug delivery |
PT1620327E (pt) * | 2003-05-02 | 2007-06-01 | Almar Packaging Internat Inc | Recipiente intermédio para produtos a granel |
EP1644019B2 (de) | 2003-05-29 | 2018-02-21 | Shire LLC | Gegen missbrauch geschützte amphetamin-verbindungen |
US20050063937A1 (en) * | 2003-09-16 | 2005-03-24 | Cheng Li | Multiple-arm peptide compounds, methods of manufacture and use in therapy |
US9763977B2 (en) | 2003-09-16 | 2017-09-19 | Incube Labs, Llc | In vitro bio-reactor circuit |
JP4691500B2 (ja) * | 2003-09-30 | 2011-06-01 | シャイア エルエルシー | 過剰摂取又は乱用を防止するための薬学組成物 |
EP1696944A4 (de) * | 2003-12-05 | 2008-11-05 | Univ Northwestern | Verzweigte peptid-amphiphile, verwandte epitope verbindungen und selbst zusammengesetzte strukturen davon |
US7544661B2 (en) | 2003-12-05 | 2009-06-09 | Northwestern University | Self-assembling peptide amphiphiles and related methods for growth factor delivery |
GB0408164D0 (en) * | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
WO2006096614A2 (en) | 2005-03-04 | 2006-09-14 | Northwestern University | Angiogenic heparin binding peptide amphiphiles |
US7964200B2 (en) | 2005-05-18 | 2011-06-21 | Children's Hospital & Research Center At Oakland | Methods and compositions for immunizing against Chlamydia infection |
WO2007027954A2 (en) * | 2005-08-30 | 2007-03-08 | Children's Hospital & Research Center At Oakland | Methods for identifying an epitope of a polypeptide, chlamydial antigenic polypeptides identified thereby, and methods of use thereof |
US8076295B2 (en) | 2007-04-17 | 2011-12-13 | Nanotope, Inc. | Peptide amphiphiles having improved solubility and methods of using same |
WO2009146885A2 (en) * | 2008-06-02 | 2009-12-10 | Spiderbiotech S.R.L. | Lipidated antibacterial peptides |
US8637040B2 (en) * | 2008-09-21 | 2014-01-28 | National Institute of Health (NIH), U.S. Dept. of Health and Human Services (DHHS) | Genus-wide chlamydial peptide vaccine antigens |
US8883967B2 (en) | 2009-03-27 | 2014-11-11 | Kansas State University Research Foundation | Branched amphipathic oligo-peptides that self-assemble into vesicles |
MX2011010780A (es) | 2009-04-13 | 2011-10-28 | Univ Northwestern | Andamios novedosos basados en peptido para la regeneracion de cartilagos y metodos para su uso. |
WO2014026033A1 (en) | 2012-08-08 | 2014-02-13 | University Of Florida Research Foundation, Inc. | Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats |
PL2976355T3 (pl) * | 2013-03-18 | 2020-07-13 | Statens Serum Institut | Szczepionki przeciwko Chlamydia sp. |
MX2016006966A (es) * | 2013-12-01 | 2017-01-19 | Univ Copenhagen | Derivados de acidos grasos de inhibidores dimericos de la proteina 95 de la densidad post-sinaptica (psd-95). |
WO2017075653A1 (en) * | 2015-11-04 | 2017-05-11 | University Of The Sunshine Coast | Chlamydia antigens and uses thereof |
GB201520558D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
US11560419B2 (en) * | 2018-12-21 | 2023-01-24 | West Virginia University | Targeting tumor microenvironments with recombinant prokaryotic collagen-like proteins |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1052699A (de) * | 1963-12-03 | |||
GB2217319A (en) * | 1988-04-19 | 1989-10-25 | Synpharm Ltd | Racemic and optically active fatty amino acids, their homo- abd hetero-oligomers and conjugates, the process of their production, their pharmaceutical composi |
GB8812214D0 (en) * | 1988-05-24 | 1988-06-29 | Hoffmann La Roche | Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope |
-
1992
- 1992-07-24 GB GB929215780A patent/GB9215780D0/en active Pending
-
1993
- 1993-07-23 DE DE69315842T patent/DE69315842T2/de not_active Expired - Fee Related
- 1993-07-23 EP EP93917902A patent/EP0652896B1/de not_active Expired - Lifetime
- 1993-07-23 AU AU47154/93A patent/AU4715493A/en not_active Abandoned
- 1993-07-23 WO PCT/GB1993/001558 patent/WO1994002506A1/en active IP Right Grant
- 1993-07-23 US US08/374,560 patent/US5882645A/en not_active Expired - Lifetime
- 1993-07-23 ES ES93917902T patent/ES2111167T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
GB9215780D0 (en) | 1992-09-09 |
EP0652896A1 (de) | 1995-05-17 |
ES2111167T3 (es) | 1998-03-01 |
US5882645A (en) | 1999-03-16 |
AU4715493A (en) | 1994-02-14 |
DE69315842D1 (de) | 1998-01-29 |
WO1994002506A1 (en) | 1994-02-03 |
EP0652896B1 (de) | 1997-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69315842T2 (de) | Peptidverbindungen | |
NO942066L (no) | Peptidderivater | |
FI931736A (fi) | Biodegraderbart tgf-b-leveranssystem foer benregeneration | |
FI930529A (fi) | Fordonshuv | |
NO306306B1 (no) | Emulsjonspolymermateriale | |
LV10962A (lv) | Jauni peptidi | |
NO930523D0 (no) | Skrukork | |
NO952430D0 (no) | Bjelkelagelement | |
DK16693A (da) | Flerskaersplov | |
LV10286A (lv) | Peptidu savienojumi | |
NO932237L (no) | Lineaere peptider | |
LV10287A (lv) | Peptidu savienojumi | |
BR9301712A (pt) | Aplainador | |
FI934724A0 (fi) | Kylbehaollare | |
FI930891A (fi) | Datakommunkationsapparat | |
DE59303468D1 (de) | Stabilisierte Aminobenzotrifluoride | |
NO922831D0 (no) | Holdeboeyle for baater | |
NO924609D0 (no) | Anodemantel for soederberganode | |
FI114U1 (fi) | Avfallkont | |
FI354U1 (fi) | Flyttanordning foer teleskopbom | |
FI527U1 (fi) | Tvaettanordning | |
FI128U1 (fi) | Klarningsbehaollarsystem | |
FI165U1 (fi) | Faesttapp | |
FI171U1 (fi) | Valvbaogskonstruktion | |
FI203U1 (fi) | Stumfoerband foer gjutformars traekonstruktioner |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |